230 related articles for article (PubMed ID: 35069416)
1. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
Front Neurol; 2021; 12():788159. PubMed ID: 35069416
[No Abstract] [Full Text] [Related]
2. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.
Blumenfeld AM; Frishberg BM; Schim JD; Iannone A; Schneider G; Yedigarova L; Manack Adams A
Pain Ther; 2021 Dec; 10(2):809-826. PubMed ID: 33880725
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
Grazzi L; Giossi R; Montisano DA; Canella M; Marcosano M; Altamura C; Vernieri F
J Headache Pain; 2024 Feb; 25(1):14. PubMed ID: 38308209
[TBL] [Abstract][Full Text] [Related]
4. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
Charleston L; Talon B; Sullivan C; Anderson C; Kymes S; Regnier SA; Soni-Brahmbhatt S; Nahas SJ
J Headache Pain; 2023 Aug; 24(1):101. PubMed ID: 37532991
[TBL] [Abstract][Full Text] [Related]
5. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
6. Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan.
Wang YF; Yang FC; Chen LA; Chang TY; Su HC; Yang CP; Tu YH; Tzeng YS; Chen SP; Fuh JL; Lai KL; Ling YH; Chen WT; Wang SJ
Eur J Neurol; 2024 Jun; ():e16372. PubMed ID: 38837528
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study.
Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
Patient Prefer Adherence; 2022; 16():821-839. PubMed ID: 35378732
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Chronic Migraine Preventive Treatments: A Systematic Literature Review.
Blumenfeld AM; Kaur G; Mahajan A; Shukla H; Sommer K; Tung A; Knievel KL
Pain Ther; 2023 Feb; 12(1):251-274. PubMed ID: 36417165
[TBL] [Abstract][Full Text] [Related]
9. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
10. Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.
Iannone LF; Fattori D; Marangoni M; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2023 Feb; 37(2):189-202. PubMed ID: 36656298
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
Alex A; Vaughn C; Rayhill M
Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
[TBL] [Abstract][Full Text] [Related]
12. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B
J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428
[TBL] [Abstract][Full Text] [Related]
13. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
15. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
16. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers.
Shibata M; Fujita K; Hoshino E; Minami K; Koizumi K; Okada S; Sakai F
BMC Neurol; 2024 Jan; 24(1):32. PubMed ID: 38238659
[TBL] [Abstract][Full Text] [Related]
17. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine.
Cohen F; Armand C; Lipton RB; Vollbracht S
Pain Med; 2021 Aug; 22(8):1857-1863. PubMed ID: 33693863
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany.
Scheffler A; Wenzel P; Bendig M; Gendolla A; Basten J; Kleinschnitz C; Nsaka M; Lindner D; Naegel S; Burow P; Fleischmann R; Holle D
J Headache Pain; 2024 May; 25(1):79. PubMed ID: 38755541
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study.
Varnado OJ; Brady BL; Zagar AJ; Robles YP; Hoyt M
Patient Prefer Adherence; 2024; 18():69-88. PubMed ID: 38223442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
